Hussein A Tawbi

Hussein A Tawbi

UNVERIFIED PROFILE

Are you Hussein A Tawbi?   Register this Author

Register author
Hussein A Tawbi

Hussein A Tawbi

Publications by authors named "Hussein A Tawbi"

Are you Hussein A Tawbi?   Register this Author

39Publications

1018Reads

23Profile Views

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

J Transl Med 2019 May 10;17(1):148. Epub 2019 May 10.

Clinical Trials Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-019-1892-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509811PMC
May 2019

Reply to A. Shinde et al.

J Clin Oncol 2019 Apr 26;37(12):1031-1032. Epub 2019 Feb 26.

Harriet M. Kluger, MD, Yale School of Medicine, New Haven, CT; Kim A. Margolin, MD, City of Hope, Duarte, CA; Michael A. Davies, MD, PhD, MD Anderson Cancer Center, Houston, TX; Georgina V. Long, PhD, The University of Sydney, Sydney, NSW, Australia; Hussein A. Tawbi, MD, PhD, MD Anderson Cancer Center, Houston, TX; and Sarah B. Goldberg, MD and Veronica L. Chiang, MD, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.02463
Publisher Site
http://dx.doi.org/10.1200/JCO.18.02463DOI Listing
April 2019

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.

J Immunother Cancer 2019 Apr 24;7(1):113. Epub 2019 Apr 24.

Department of Medicine, University of Pittsburgh, UPMC Hillman Cancer Center, 5117 Centre Avenue, Suite 1.27, Pittsburgh, PA, 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0552-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480917PMC
April 2019

Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 11;379(22):2178

City of Hope, Duarte, CA

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1812500
Publisher Site
http://dx.doi.org/10.1056/NEJMc1812500DOI Listing
November 2018

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

J Clin Oncol 2018 Oct 25:JCO1800632. Epub 2018 Oct 25.

Diwakar Davar, Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, Julien J. Fourcade, Mignane Ka, Carmine Menna, Amy Rose, Cindy Sander, Amir A. Borhani, Arivarasan Karunamurthy, John M. Kirkwood, and Hassane M. Zarour, University of Pittsburgh, Pittsburgh, PA ; Ahmad A. Tarhini, Cleveland Clinic, Cleveland, OH; Hussein A. Tawbi, The University of Texas MD Anderson Cancer Center, Houston, TX; and Qing Zhao, Blanca H. Moreno, Scott Ebbinghaus, and Nageatte Ibrahim, Merck, Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00632
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00632DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286160PMC
October 2018

Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!

Cancer Discov 2018 08;8(8):914-917

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0618DOI Listing
August 2018

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 Aug;379(8):722-730

From the University of Texas M.D. Anderson Cancer Center, Houston (H.A.T.); Moffitt Cancer Center and Research Institute, Tampa, FL (P.A.F., N.I.K.); University of California-San Francisco, San Francisco (A. Algazi), the Angeles Clinic and Research Institute, Los Angeles (O.H.), Stanford University Hospital, Palo Alto (R.P.T.), and the Department of Medical Oncology, City of Hope, Duarte (K.M.) - all in California; Dana-Farber Cancer Institute, Boston (F.S.H., D.A.R.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (S.J.M.); University of Colorado Comprehensive Cancer Center, Aurora (K.L.); University of Michigan, Ann Arbor (C.D.L.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.A.P.), Roswell Park Cancer Institute, Buffalo (M.S.E., I.P.), and New York University, Lake Success (A.C.P.) - all in New York; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); Winship Cancer Institute of Emory University, Atlanta (R.R.K.); University of Pittsburgh Medical Center, Pittsburgh (A.T.); Bristol-Myers Squibb, Princeton, NJ (J.J., A. Avila, S.D.); and Cleveland Clinic-Taussig Cancer Institute, Cleveland (A.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805453DOI Listing
August 2018

New Era in the Management of Melanoma Brain Metastases.

Am Soc Clin Oncol Educ Book 2018 May;38:741-750

From The University of Texas MD Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, Paris, France; Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200819DOI Listing
May 2018

PD-1 inhibition in sarcoma still needs investigation - Authors' reply.

Lancet Oncol 2018 01;19(1):e7

Department of Medicine, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30922-1DOI Listing
January 2018

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.

J Immunother Cancer 2017 09 19;5(1):74. Epub 2017 Sep 19.

Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0279-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604296PMC
September 2017

Retinal imaging with en face and cross-sectional optical coherence tomography delineates outer retinal changes in cancer-associated retinopathy secondary to Merkel cell carcinoma.

J Ophthalmic Inflamm Infect 2015 Dec 19;5(1):53. Epub 2015 Aug 19.

Department of Ophthalmology, UPMC Eye Center, Eye and Ear Institute, Ophthalmology and Visual Science Research Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12348-015-0053-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540718PMC
December 2015

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 12;20(7):1900-9. Epub 2014 Feb 12.

Authors' Affiliations: Vall d'Hebron Institut d'Oncologia and Universitat Autonoma of Barcelona, Barcelona, Spain; University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; University of Leicester, Leicester, United Kingdom; University Hospital of Zürich, Zürich, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, New York; Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1710DOI Listing
April 2014

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Cancer Res 2014 Feb 16;74(4):1045-55. Epub 2013 Dec 16.

Authors' Affiliations: Division of Hematology/Oncology, Department of Medicine; Departments of Immunology and Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Pfizer, Cambridge; and Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2908DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952491PMC
February 2014

Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.

Cancer Chemother Pharmacol 2013 Nov 14;72(5):1143-7. Epub 2013 Sep 14.

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27D, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2283-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818249PMC
November 2013

Melanoma brain metastases: an unmet challenge in the era of active therapy.

Curr Oncol Rep 2013 Oct;15(5):483-91

Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-013-0335-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801214PMC
October 2013

A potential role for nilotinib in KIT-mutated melanoma.

Expert Opin Investig Drugs 2012 Jun 16;21(6):861-9. Epub 2012 Apr 16.

University of Pittsburgh, School of Medicine, Division of Hematology/Oncology, Department of Medicine, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/13543784.2012.67
Publisher Site
http://dx.doi.org/10.1517/13543784.2012.679341DOI Listing
June 2012

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

J Clin Oncol 2012 Jan 19;30(3):322-8. Epub 2011 Dec 19.

University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Ave, Fifth Fl, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.37.5394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422533PMC
January 2012

Chemotherapy resistance abrogation in metastatic melanoma.

Clin Adv Hematol Oncol 2010 Apr;8(4):259-66

University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
April 2010

Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?

Nat Clin Pract Oncol 2009 Feb 17;6(2):70-1. Epub 2008 Dec 17.

Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/ncponc1297
Publisher Site
http://dx.doi.org/10.1038/ncponc1297DOI Listing
February 2009

Management of metastatic melanoma.

Semin Oncol 2007 Dec;34(6):532-45

Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2007.09.008DOI Listing
December 2007

Calcitonin in the treatment of transient osteoporosis of the hip.

Semin Arthritis Rheum 2003 Jun;32(6):388-97

Departments of Internal Medicine, Obstetrics and Gynecology and Diagnostic Radiology, American University of Beirut, Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/sarh.2002.50014DOI Listing
June 2003